Neurogene (NGNE)

• Market cap: $218M
• 1 day: -0.91%
• 5 days: 42.33%
• 1 month: 9.60%
• 3 months: 1.59%
• 6 months: -68.26%
• Year to date: -33.16%
• 1 year: -49.39%
• 5 years: -75.58%
• 10 years: -60.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Employees: 107

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

1% more funds holding

Funds holding: 86 [Q3] → 87 (+1) [Q4]

8% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 25

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

29.91% less ownership

Funds ownership: 106.6% [Q3] → 76.69% (-29.91%) [Q4]

37% less capital invested

Capital invested by funds: $581M [Q3] → $368M (-$213M) [Q4]

44% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $5.52M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 5% upside
• Avg. target: $33 116% upside
• High target: $50 227% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

BMO Capital Keith Tapper 17% 1-year accuracy 1 / 6 met price target	5% upside $16	Outperform Maintained	14 Apr 2025
HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 55 / 185 met price target	227% upside $50	Buy Maintained	25 Mar 2025